Madrigal sees a stock sell-off; ex-Novartis exec heads to Daiichi

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Today, a brief rundown of news from Madrigal Pharmaceuticals and Daiichi Sankyo, as well as updates from Johnson & Johnson, AC Immune and Novartis that you may have missed. Shares of Madrigal Pharmaceuticals fell by double digits on Thursday despite quarterly numbers for its liver disease drug Rezdiffra that again surpassed consensus estimates. Rezdiffra four ...